You are here

ENHANCED ROLLER BOTTLE

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44GM058978-02A1
Agency Tracking Number: GM058978
Amount: $1,058,903.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
WILSON WOLF MANUFACTURING CORP. 151 SILVER LAKE RD NW
NEW BRIGHTON, MN 55112
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN WILSON
 (651) 628-9259
 WWMFGCORP@AOL.COM
Business Contact
 JOHN WILSON
Phone: (612) 628-9259
Email: WWMFGCORP@AOL.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant)Advances in large-scale production of mammalian cells or their secreted proteins have led to the licensure of many therapeutic and diagnostic products. Culture devices, such as stirred-tank and hollow fiber bioreactors, have utility in large-scale production, but are impractical and cost prohibitive at the research scale. Traditional roller bottles have been used successfully for small to mid-scale production of recombinant proteins, viral vectors, and therapeutic cell doses, but are labor intensive, typically requiring more than ten devices for each desired product. The Enhanced Roller Bottle (ERB) is a practical, cost effective cell culture device designed to improve culture productivity. The ERB increased cell production 4- to 9-fold over the traditional roller bottle by increased surface area for cell attachment and increased availability of culture medium due to its gas permeable walls. In the proposed Phase II studies, the ERB will be optimized for the production of anchorage-dependent cells and cell-secreted products. ERB parameters requiring investigation include gas transfer, scaffold configuration and material, inoculation methods, operating conditions, and product recovery. At the completion of Phase II, the ERB will be targeted to manufacturers of small and mid-scale culture devices for the production of cells or cell products for diagnostic and therapeutic applications.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government